These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7699528)

  • 1. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group.
    Eigen H; Rosenstein BJ; FitzSimmons S; Schidlow DV
    J Pediatr; 1995 Apr; 126(4):515-23. PubMed ID: 7699528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.
    Auerbach HS; Williams M; Kirkpatrick JA; Colten HR
    Lancet; 1985 Sep; 2(8457):686-8. PubMed ID: 2863676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis.
    Lai HC; FitzSimmons SC; Allen DB; Kosorok MR; Rosenstein BJ; Campbell PW; Farrell PM
    N Engl J Med; 2000 Mar; 342(12):851-9. PubMed ID: 10727589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis.
    Schnabel D; Grasemann C; Staab D; Wollmann H; Ratjen F;
    Pediatrics; 2007 Jun; 119(6):e1230-8. PubMed ID: 17545356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
    JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral steroids for cystic fibrosis.
    Cheng K; Ashby D; Smyth R
    Cochrane Database Syst Rev; 2000; (2):CD000407. PubMed ID: 10796717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
    Ramsey BW; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Kravitz RM; Schidlow DV; Wilmott RW; Astley SJ; McBurnie MA
    N Engl J Med; 1993 Jun; 328(24):1740-6. PubMed ID: 8497284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group.
    Pons G; Marchand MC; d'Athis P; Sauvage E; Foucard C; Chaumet-Riffaud P; Sautegeau A; Navarro J; Lenoir G
    Pediatr Pulmonol; 2000 Jul; 30(1):25-31. PubMed ID: 10862159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa.
    Kerem E; Corey M; Gold R; Levison H
    J Pediatr; 1990 May; 116(5):714-9. PubMed ID: 2109790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
    Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of high-dose ibuprofen in patients with cystic fibrosis.
    Konstan MW; Byard PJ; Hoppel CL; Davis PB
    N Engl J Med; 1995 Mar; 332(13):848-54. PubMed ID: 7503838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.
    Schmitt-Grohé S; Zielen S
    Paediatr Drugs; 2005; 7(6):353-63. PubMed ID: 16356023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
    Ranasinha C; Assoufi B; Shak S; Christiansen D; Fuchs H; Empey D; Geddes D; Hodson M
    Lancet; 1993 Jul; 342(8865):199-202. PubMed ID: 8100928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.